ArticleSurgery2026
Evaluation of exogenous estrogen use in patients with lobular neoplasia and its role in subsequent breast cancer development.
Article in Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThere is a paucity of data regarding the impact of exogenous hormones on future breast cancer risk in the setting of lobular neoplasia. We sought to determine if patients with a history of exogenous hormone use who develop lobular neoplasia are more likely to develop future breast cancer.
methodsFollowing institutional review board approval, a single-institution retrospective review was conducted of patients diagnosed with lobular carcinoma in situ or atypical lobular hyperplasia between January 2009 and December 2017. The use of exogenous hormones and future breast cancer were examined. Data were analyzed using IBM SPSS, version 29.0.2.0.
resultsA total of 88 patients with lobular neoplasia were identified: 57 (65%) with lobular carcinoma in situ and 31 (35%) with atypical lobular hyperplasia. At the time of lobular neoplasia diagnosis, 53 (60%) underwent surgical excision, 48 (39%) were followed in a high-risk clinic, and 13 (15%) took antiestrogen therapy for risk reduction. Fifteen patients had a history of hormone therapy use prior to lobular neoplasia diagnosis (17%), and 3 (3%) started hormone therapy following lobular neoplasia diagnosis. Median overall follow-up was 9.7 years (interquartile range, 7.2-11.4). Eleven (13%) patients developed breast cancer. Comparing those who developed breast cancer versus those who did not, there was no difference in hormone therapy use (9% vs 21%, P = .325), vaginal estrogen use (27% vs 9%, P = .110), oral contraceptive pill use (54% vs 64%, P = .675), or other hormone-based birth control (27% vs 14%, P = .402).
conclusionIn a single-institution cohort with long-term follow-up, the future development of breast cancer in patients diagnosed with lobular neoplasia was not associated with prior use of hormone therapy, oral contraceptive pills, vaginal estrogen, or other hormone-based birth control.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.